ArticleCardio-oncology (London, England)2026
Long-term outcomes of prophylactic cardioprotection in early-stage breast cancer patients on non-anthracycline anti-HER2 therapy.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-HER2 therapy has improved survival in HER2-positive breast cancer patients for decades but is associated with well-established cardiotoxicity. Our prior randomized controlled trial PROTECT HER2 found no short-term benefit of prophylactic beta-blocker cardio protection (CPT) based on changes in global longitudinal strain (GLS) in a breast cancer population treated with non-anthracycline anti-HER2 therapies. The long-term cardiovascular (CV) effects of CPT remain unknown. Utilizing the PROTECT HER2 cohort with 5-10 years follow-up, we performed a post hoc analysis to assess long-term outcomes. We evaluated the incidence of major adverse cardiovascular events (MACE; defined as all-cause mortality, stroke, myocardial infarction (MI), heart failure hospitalization (HFH), and significant arrhythmias) based on CPT. We also assessed associations between CV risk factors (hypertension, hyperlipidemia, diabetes and BMI≥25 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.